Here, the severity of IL-1β-induced arthritis was dampened by anti-SAA Ab treatment, which suggests that SAA can be targeted to retard IL-1β–dependent arthritides, including gouty arthritis and collagen-induced arthritis (46, 47). This evidence concerns the gene SAA2 and arthritic joint disease.